[68Ga]Ga-DOTA.SA.FAPi与[18F]F-FDG PET/CT在放射性碘抵抗滤泡细胞来源甲状腺癌中的头对头比较
回顾性纳入117例放射性碘抵抗滤泡细胞来源甲状腺癌患者,比较[68Ga]Ga-DOTA.SA.FAPi与[18F]F-FDG PET/CT的检测能力。[68Ga]Ga-DOTA.SA.FAPi对淋巴结、肝、脑转移检出率更高,脑和肌肉转移的SULpeak更高。作者认为其有潜力作为诊疗一体化工具补充[18F]F-FDG PET/CT。
要点
- [68Ga]Ga-DOTA.SA.FAPi对淋巴结转移检出率95.4% vs 86.6%(p<0.0001)。
- [68Ga]Ga-DOTA.SA.FAPi对肝转移检出率100% vs 81.3%(p<0.0001),脑转移100% vs 39%(p<0.0001)。
- 脑转移SULpeak 13.9 vs 6.7(p-0.0001),肌肉转移9.56 vs 5.62(p-0.0085),FAPi更高。
核心结论
- [68Ga]Ga-DOTA.SA.FAPi在检测淋巴结、肝、肠和脑转移方面优于[18F]F-FDG PET/CT。
- 作者认为[68Ga]Ga-DOTA.SA.FAPi有潜力作为诊疗一体化工具,补充[18F]F-FDG PET/CT在放射性碘抵抗滤泡细胞来源甲状腺癌成像中的价值。
研究设计与样本
- 回顾性研究,纳入117例放射性碘抵抗滤泡细胞来源甲状腺癌患者,其中女性68例、男性49例,平均年龄53.2±11.7岁。
- 对[68Ga]Ga-DOTA.SA.FAPi与[18F]F-FDG PET/CT进行定性和定量评估,定性包括基于患者和基于病灶的视觉判读比较,定量分析采用瘦体重校正的标准化摄取值(SULpeak和SULavg)。
- 扫描结果通过与诊断性CT的形态学表现和/或组织病理学检查进行验证。
主要发现
- 117例患者中60例为单侧局部病变,9例为双侧病变,两种PET扫描检出率完全一致。
- [68Ga]Ga-DOTA.SA.FAPi对淋巴结转移检出率95.4% vs [18F]F-FDG 86.6%(p<0.0001),肝转移100% vs 81.3%(p<0.0001),脑转移100% vs 39%(p<0.0001)。
- 胸膜和骨转移检出率两种示踪剂相似;肺转移[68Ga]Ga-DOTA.SA.FAPi检出率81.7%,[18F]F-FDG为64.6%。
- [68Ga]Ga-DOTA.SA.FAPi检出1处[18F]F-FDG扫描漏检的肠转移。
- 中位SUL总体可比,但脑转移SULpeak [68Ga]Ga-DOTA.SA.FAPi 13.9 vs [18F]F-FDG 6.7(p-0.0001)、肌肉转移9.56 vs 5.62(p-0.0085),[68Ga]Ga-DOTA.SA.FAPi摄取更高。
关键数值与推荐
- 淋巴结转移检出率:[68Ga]Ga-DOTA.SA.FAPi 95.4% vs [18F]F-FDG 86.6%(p<0.0001)。
- 肝转移检出率:[68Ga]Ga-DOTA.SA.FAPi 100% vs [18F]F-FDG 81.3%(p<0.0001)。
- 脑转移检出率:[68Ga]Ga-DOTA.SA.FAPi 100% vs [18F]F-FDG 39%(p<0.0001)。
- 脑转移SULpeak:[68Ga]Ga-DOTA.SA.FAPi 13.9 vs [18F]F-FDG 6.7(p-0.0001)。
- 肌肉转移SULpeak:[68Ga]Ga-DOTA.SA.FAPi 9.56 vs [18F]F-FDG 5.62(p-0.0085)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the context of radioiodine-resistant follicular-cell derived thyroid cancers (RAI-R-FCTC), [18F]F-FDG PET/CT serves as a widely used and valuable diagnostic imaging method. However, there is growing interest in utilizing molecular imaging probes that target cancer-associated fibroblasts (CAFs) as an alternative approach. This study sought to compare the diagnostic capabilities of [68Ga]Ga-DOTA.SA.FAPi and [18F]F-FDG PET/CT in patients with RAI-R-FCTC. METHODS: In this retrospective study, a total of 117 patients with RAI-R-FCTC were included. The study population consisted of 68 females and 49 males, with a mean age of 53.2 ± 11.7 years. The aim of the study was to perform a comprehensive qualitative and quantitative assessment of [68Ga]Ga-DOTA.SA.FAPi and [18F]F-FDG PET/CT scans in RAI-R-FCTC patients. The qualitative assessment involved comparing patient-based and lesion-based visual interpretations of both scans, while the quantitative assessment included analyzing standardized uptake values corrected for lean body mass (SULpeak and SULavg). The findings obtained from the scans were validated by correlating them with morphological findings from diagnostic computed tomography and/or histopathological examination. RESULTS: Among the 117 RAI-R-FCTC patients, 60 had unilateral local disease, and 9 had bilateral lesions with complete concordance in the detection rate on both PET scans. [68Ga]Ga-DOTA.SA.FAPi had a higher detection rate for lymph nodes (95.4% vs 86.6%, p<0.0001), liver metastases (100% vs. 81.3%, p<0.0001), and brain metastases (100% vs. 39%, p<0.0001) compared to [18F]F-FDG. The detection rates for pleural and bone metastases were similar between the two radiotracers. For lung metastases, [68Ga]Ga-DOTA.SA.FAPi showed a detection rate of 81.7%, whereas [18F]F-FDG had a detection rate of 64.6%. Remarkably, [68Ga]Ga-DOTA.SA.FAPi was able to detect a bowel metastasis that was missed on [18F]F-FDG scan. The median standardized uptake values (SUL) were generally comparable between the two radiotracers, except for brain metastases (SULpeak [68Ga]Ga-DOTA.SA.FAPi vs. [18F]F-FDG: 13.9 vs. 6.7, p-0.0001) and muscle metastases (SULpeak [68Ga]Ga-DOTA.SA.FAPi vs. [18F]F-FDG: 9.56 vs. 5.62, p-0.0085), where [68Ga]Ga-DOTA.SA.FAPi exhibited higher uptake. CONCLUSION: The study results demonstrate the superior performance of [68Ga]Ga-DOTA.SA.FAPi compared to [18F]F-FDG PET/CT in detecting lymph nodal, liver, bowel, and brain metastases in patients with RAI-R-FCTC. These findings highlight the potential of [68Ga]Ga-DOTA.SA.FAPi as a theranostic tool that can complement the benefits of [18F]F-FDG PET/CT in the imaging of RAI-R-FCTC.
引用
- Ballal S, Yadav MP, Roesch F, et al. Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi with [18F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancers. Eur J Nucl Med Mol Imaging. 2023. PMID: 37642703. doi:10.1007/s00259-023-06404-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。